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Abstract
Chronic lymphocytic leukemia cells (CLL) migrate between the blood and lymphoid tissues in response to chemokines.
Such migration requires structured cytoskeletal-actin polymerization, which may involve the protein cortactin. We
discovered that treatment of CLL cells with Wnt5a causes Receptor tyosin kinase-like orphan receptor 1 (ROR1) to bind
cortactin, which undergoes tyrosine phosphorylation at Y421, recruits ARHGEF1, and activates RhoA, thereby enhancing
leukemia-cell migration; such effects could be inhibited by cirmtuzumab, a humanized mAb specific for ROR1. We
transfected the CLL-cell-line MEC1 with either full-length ROR1 or various mutant forms of ROR1 to examine the
structural features required for binding cortactin. We found that the proline-rich domain (PRD) was necessary for ROR1 to
recruit cortactin. We generated MEC1 cells that each expressed a mutant form of ROR1 with a single amino-acid
substitution of alanine (A) for proline (P) in potential SH3-binding sites in the ROR1-PRD at positions 784, 808, 826, 841,
or 850. In contrast to wild-type ROR1, or other ROR1P=>A mutants, ROR1P(841)A failed to complex with cortactin or
ARHGEF1 in response to Wnt5a. Moreover, Wnt5a could not induce MEC1-ROR1P(841)A to phosphorylate cortactin or
enhance CLL-cell F-actin polymerization. Taken together, these studies show that cortactin plays an important role in
ROR1-dependent Wnt5a-enhanced CLL-cell migration.
Introduction
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a
highly conserved surface protein that ordinarily functions in
the organogenesis of skeletal and neural tissues [1–4]. The
expression of ROR1 attenuates during fetal development
[5], becoming negligible on most tissues at term [6].
However, we and others have found that ROR1 dis-
tinctively is expressed on the leukemia cells of most patients
with chronic lymphocytic leukemia (CLL) [6–8], suggest-
ing that it may play a pathogenic role. Consistent with this
concept are studies demonstrating that high-level leukemia-
cell expression of ROR1 can enhance disease progression in
mouse models [9], and associate with a shorter median time
from diagnosis to initial therapy and shorter survival for
patients with CLL [10].
We described that Wnt5a could act as a ligand for ROR1
[6], which prior studies showed could enhance directional
cell migration and planar-cell polarity by inducing non-
canonical Wnt signaling [11]. In more recent studies on
CLL cells, we described that Wnt5a could induce ROR1 to
recruit and activate guanine exchange factors (GEFs), and
thereby enhance leukemia-cell migration and proliferation
[12]. These effects of Wnt5a on CLL cells could be
inhibited by cirmtuzumab (UC-961), a humanized mAb
specific for ROR1. However, the molecular mechanism(s)
for how ROR1 exerts these effects and how cirmtuzumab
could inhibit such outcomes are still unclear.
Cortactin (also called EMS1, or CTTN) plays an important
role in the reorganization of the cytoskeleton required for
migration and planar-cell polarity. Cortactin is a cytoplasmic
protein that can promote polymerization and rearrangement of
the actin cytoskeleton required for cell migration upon its
tyrosine phosphorylation or activation [13–15]. Cortactin
contains a SH3 domain, which allows it to bind in the proline-
rich-domain (PRD) of other proteins at characteristic
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SH3-binding motifs (-P-X-X-P-) [16–18]. Cortactin also is
expressed in CLL cells and the CLL-cell-line MEC1 [19, 20].
Moreover, expression and phosphorylation of cortactin cor-
relate with enhanced CLL-cell migration [19, 21]. However,
the role of Wnt5a in the phosphorylation of cortactin was
unknown. Here we report our studies evaluating whether
cortactin is recruited to ROR1 upon stimulation with Wnt5a,
undergoes tyrosine phosphorylation, and recruits/activates
ARHGEF1 to promote F-actin polymerization and leukemia-
cell migration.
Materials and methods
Cell culture and CLL specimens
MEC1 cells were cultured in RPMI medium with 10% FBS,
1% penicillin/streptomycin and maintained at 37 °C in a
humidified atmosphere of 5% CO2, and tested negative for
mycoplasma contamination. Media and supplements were
purchased from Life Technologies (Carlsbad, CA, USA).
Blood samples were collected from CLL patients at the
Moores Cancer Center. Peripheral blood mononuclear cells
were isolated by density centrifugation with Ficoll-Paque
PLUS (GE Healthcare Life Sciences) and suspended in 90%
FBS (Omega Scientific) and 10% DMSO (Sigma-Aldrich)
for viable storage in liquid nitrogen.
Statistical analysis
Data are presented as mean ± SD. Differences between two
groups were determined by unpaired two-tailed Student’s
t-test. Differences between multiple groups were deter-
mined by one-way ANOVA with post-hoc Tukey HSD test.
All P values of less than 0.05 were considered significant.
Analysis for significance was performed with GraphPad
Prism 6.0 (GraphPad Software Inc.).
Fig. 1 Phosphorylation of cortactin is high in ROR1Pos CLL. a
Immunoblot analysis of lysates prepared from primary ROR1Pos or
ROR1Neg CLL cells of different patients; filters were probed with anti-
cortactin, anti-phospho-cortactin (anti-pCortactin (Y421)), or anti-
ROR1 antibody, as indicated on the left. The numbers above the top
lane are ratios of band integrated optical density (IOD) of phos-
phorylated versus total cortactin. b Phosphorylation of cortactin (at
Y421) was assessed by immunoblot analysis of lysates prepared from
primary CLL cells of different patients with CLL cells that did
(ROR1Pos (n= 13)) or did not (ROR1Neg (n= 11)) express ROR1. The
ratios of band IOD of phosphorylated versus total cortactin were
determined and plotted in the graph. Data are shown as mean ± SD. P
< 0.001, as assessed by two-tailed Student’s t-test
Fig. 2 Association of ROR1 with cortactin in primary CLL cells. a
Immunoblot analysis of anti-ROR1 ip or control IgG (Ctrl-IgG) ip, as
indicated at the top, using lysates prepared from freshly isolated primary
CLL cells; the filters were probed with anti-ROR1 or anti-cortactin
antibody, as indicated on the left. b Immunoblot analysis of anti-cortactin
ip or Ctrl-IgG ip, as indicated at the top, using lysates prepared from
freshly isolated primary CLL cells; the filters were probed with anti-
ROR1 or anti-cortactin antibody, as indicated on the left. c Immunoblot
analysis of anti-ROR1 ip using lysates prepared from overnight, serum-
starved primary CLL cells that subsequently were treated for 30min
without (–) or with (+) Wnt5a (100 ng/ml), as indicated on the top; the
filters were probed with anti-ROR1 or anti-cortactin antibody, as indi-
cated on the left. d Immunoblot analysis of anti-ROR1 ip, as indicated at
the top, using lysates prepared from serum-starved primary CLL cells
that had been treated with cirmtuzumab, without (–) or with (+) Wnt5a
(100 ng/ml); filters were probed with anti-ROR1 or anti-cortactin anti-
body, as indicated on the left. An immunoblot of the whole-cell lysates
(“Cell lysate”) of the CLL cells treated without or with cirmtuzumab and
probed with anti-cortactin mAb is provided in the bottom panel
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Results
Tyrosine phosphorylation of cortactin is higher in
ROR1Pos CLL
Prior studies found that cortactin may be constitutively
phosphorylated at Y421 in freshly isolated CLL cells [21].
Since other studies found that ROR1 is variably expressed
on the CLL cells of different patients [22], we examined for
expression of cortactin and phosphorylated cortactin in CLL
cells that expressed ROR at high levels (ROR1Pos CLL)
versus low-to-negligible levels (ROR1Neg CLL). We found
that the amount of cortactin did not vary between such
samples (Fig. 1a, upper panel). However, the mean level of
cortactin that was phosphorylated at Y421 (pCortactin) and
the ratio of pCortactin/cortactin were significantly higher in
ROR1Pos CLL (n= 13) than in ROR1Neg CLL cells (n= 11)
(P < 0.001) (Fig. 1a, b).
Wnt5a induces ROR1/cortactin association in
primary CLL cells
We performed immunoblot analysis of anti-ROR1 or anti-
cortactin ip and found that ROR1 complexed with cortactin
in freshly isolated primary CLL cells (Fig. 2a, b). However,
this complex was not apparent in CLL cells that were cul-
tured overnight in media lacking Wnt5a. When we exam-
ined serum-starved CLL cells that were cultured for 30 min
in complete media without or with exogenous Wnt5a, we
found that the Wnt5a-treated CLL cells again had ROR1
complexed with cortactin (Fig. 2c). Treatment of CLL cells
with the ant-ROR1 antibody cirmtuzumab could block the
capacity of Wnt5a to induce cortactin to complex with
ROR1, as assessed in immunoblot analysis of ip generated
from treated CLL cells using an anti-ROR1 mAb (4A5)
specific for a different epitope than that recognized by cir-
mtuzumab (Fig. 2d).
Wnt5a induces ROR1-dependent cortactin
phosphorylation and enhances CLL-cell migration
We cultured CLL cells in media lacking Wnt5a and
observed attrition in the level of phosphorylated cortactin
over time (Supplementary Figure S1). Treatment of Wnt5a-
starved CLL cells with exogenous Wnt5a for 5 min induced
tyrosine phosphorylation of cortactin (Fig. 3a). However,
pre-treatment of CLL cells with cirmtuzumab blocked
the ability of Wnt5a to induce tyrosine phosphorylation of
cortactin (Fig. 3b), indicating that Wnt5a induced tyrosine
phosphorylation of cortactin in a ROR1-dependent manner.
Previously we reported that CLL cells treated with
Wnt5a could enhance migration directed by chemokines
such as CXCL12, and cirmtuzumab could inhibit such
effects [12, 23]. We found that treatment of CLL cells with
cortactin-specific siRNA, but not non-specific siRNA, could
reduce expression of cortactin and suppress the capacity of
Wnt5a to enhance chemokine-directed CLL-cell migration
(Fig. 3c, d). We also examined the motility of CLL-cells co-
cultured with marrow mesenchymal stromal cells (MSCs)
cultured at a physiologic oxygen tension (e.g., 5% O2 in
N2). Such MSCs secrete CXCL12 or Wnt5a, as described
[24, 25]. We found that co-culture with stromal cells
enhanced the migration capacity of CLL cells. However,
silencing the expression of cortactin with specific siRNA, or
treatment with anti-ROR1 antibody, could significantly
inhibit the motility of CLL cells co-cultured with stromal
cells, indicating that ROR1/cortactin-signaling plays
an important role in CLL-cell migration (Supplementary
Figures S2 A and B).
Fig. 3 Wnt5a induces ROR1-dependent phosphorylation of cortactin
and enhances chemokine-directed leukemia-cell migration. a Immu-
noblot analysis of lysates prepared from overnight, serum-starved
primary CLL cells that subsequently were treated for 5 min without (–)
or with (+) Wnt5a (100 ng/ml), as indicated on the top; the filters were
probed with anti-cortactin or anti-pCortactin (Y421) antibody, as
indicated on the left. b Immunoblot analysis of lysates prepared from
overnight, serum-starved primary CLL cells that subsequently were
treated with Ctrl-IgG or cirmtuzumab (10 μg/ml), without (–) or with
(+) Wnt5a (100 ng/ml), as indicated on the top; the filters were probed
with anti-cortactin or anti-pCortactin (Y421) antibody, as indicated on
the left. c Immunoblot analysis of lysates prepared from CLL-cells
transfected 72 h before with control siRNA or siRNA targeting cor-
tactin; filters were probed with anti-cortactin or anti-β-actin antibody,
as indicated on the left. Cell viability was over 85% in control-and
cortactin-siRNA transfected cells. d CLL-cell migration in response to
CXCL12 (200 ng/ml) was assessed without (–) or with (+) exogenous
Wnt5a (200 ng/ml), as indicated at the bottom. Data are shown as
mean ± SD from three independent experiments of CLL cells from
each of six patients. P < 0.05; P < 0.01; P < 0.001, as assessed by two-
tailed Student’s t-test
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Previously we described that HS1 contributed to the
capacity of Wnt5a to enhance leukemia-cell migration [23].
Here we found that silencing both cortactin and HS1 had an
additive effect in inhibiting Wnt5a-induced chemokine-
directed migration of CLL cells. Moreover, the inhibitory
effect of silencing both cortactin and HS1 was significantly
greater than that caused by silencing either cortactin or HS1
alone (Supplementary Figure S3).
ROR1 associates with cortactin, which undergoes
tyrosine phosphorylation in MEC1-ROR1 cells
MEC1 is a cell-line derived from CLL cells that has been
used as a cell model system for CLL [26]. In prior studies,
we found that MEC1 does not express ROR1, but expresses
high levels of Wnt5a [12]. We transfected MEC1 cells with
a ROR1-expression plasmid to generate MEC1-ROR1 cells,
which express human ROR1. We performed immunoblot
analysis of anti-ROR1 or anti-cortactin ip and found that
ROR1 associated with cortactin in MEC1-ROR1 cells
(Fig. 4a, b). As expected, ROR1 was not detected in the
anti-cortactin ip using lysates of MEC1 cells lacking ROR1
(Fig. 4c). Consistent with the dependency of cortactin
phosphorylation on ROR1, we found that MEC1-ROR1
cells showed higher-levels of phosphorylated cortactin than
MEC1 cells, which had negligible levels of
phosphorylated cortactin (Fig. 4d). Treatment of MEC1-
ROR1 cells with neutralizing antibodies to Wnt5a caused
ROR1 to dissociate from cortactin (Fig. 4e), and reduced
the levels of phosphorylated cortactin in a time-dependent
manner (Fig. 4f).
ARHGEF1 associates with ROR1/cortactin and
enhances activation of RhoA
MEC1-ROR1 cells have higher levels of activated RhoA
than MEC1 cells lacking ROR1 [12, 23]. These prior stu-
dies showed that ARHGEF1 was recruited to ROR1 and
affected activation of RhoA [12, 23]. Here, we performed
immunoblot analysis of anti-cortactin or anti-ARHGEF1 ip
Fig. 4 ROR1 in MEC1-ROR1 cells associates with cortactin, which
undergoes Wnt5a-dependent phosphorylation at Y421. a Immunoblot
analysis of anti-ROR1 ip or Ctrl-IgG ip, as indicated at the top, using
lysates prepared from MEC1-ROR1 cells; the filters were probed with
anti-ROR1 or anti-cortactin antibody, as indicated on the left. b
Immunoblot analysis of anti-cortactin ip or Ctrl-IgG ip, as indicated at
the top, using lysates prepared from MEC1-ROR1 cells; filters were
probed with anti-ROR1 or anti-cortactin antibody, as indicated on the
left. c Immunoblot analysis of anti-cortactin ip or Ctrl-IgG ip, as
indicated at the top, using lysates prepared from the ROR1-negative
cell line, MEC1; the filters were probed with anti-ROR1 or anti-
cortactin antibody, as indicated on the left. d Immunoblot analysis of
lysates prepared from MEC1 or MEC1-ROR1 cells, as indicated on
the top; filters were probed with anti-cortactin, anti-pCortactin (Y421),
or ROR1 antibody, as indicated on the left. e Immunoblot analysis of
anti-ROR1 ip or Ctrl-IgG ip, as indicated at the top, using lysates
prepared from MEC1-ROR1 cells that had been treated with a Wnt5a
neutralizing antibody (2 µg/ml, R&D, Cat#MAB645) for the times
indicated at the bottom (in hours); filters were probed with anti-ROR1
or anti-cortactin antibody, as indicated on the left. An immunoblot of
the whole-cell lysates of the MEC1-ROR1 cells treated with the Wnt5a
neutralizing antibody and probed with an anti-cortactin mAb is pro-
vided in the bottom panel. f Immunoblot analysis of lysates prepared
from MEC1-ROR1 cells that had been treated with a Wnt5a neu-
tralizing antibody (2 µg/ml, R&D) for the times indicated at the top (in
hours); filters were probed with anti-cortactin, anti-pCortactin (Y421),
as indicated on the left. An immunoblot of the whole-cell lysates of the
MEC1-ROR1 cells treated with the Wnt5a neutralizing antibody and
probed with anti-cortactin mAb is provided in the bottom panel
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from lysates of freshly isolated CLL cells, and found that
cortactin was associated with ARHGEF1 (Fig. 5a, b).
Reducing expression of cortactin via treatment with cor-
tactin siRNA, but not control siRNA, inhibited in the
capacity of Wnt5a to induce activation of RhoA by anti-
ARHGEF1 ip (Fig. 5c) and reduced the level of activated
RhoA in MEC1-ROR1 cells (Fig. 5d), indicating that cor-
tactin contributed to Wnt5a-induced activation of RhoA.
Proline at position 841 of ROR1 is required for it to
associate and activate cortactin
In structure cortactin contains a SH3 domain, which can
bind to proteins with a PRD such as ROR1, at -P-X-X-P-
motifs [1, 16–18]. We examined whether the PRD of ROR1
was required for ROR1 to associate with cortactin. For this,
we transfected MEC1 cells with an expression vector
encoding wild-type (WT) ROR1 or ΔPRD-ROR1 (ROR1
lacking the PRD) to generate MEC1 cells that
both expressed surface ROR1 (Fig. 6a, b). Although
the anti-ROR1 ip from lysates of MEC1-W/T ROR1 con-
tained cortactin (Fig. 6d), the anti-ROR1 ip from lysates of
MEC1-ΔPRD-ROR1 cells did not contain any detectable
cortactin (Fig. 6d).
Since the PRD of ROR1 was necessary for ROR1 to
associate with cortactin, we generated various mutant
forms of ROR1 that had proline (P) to alanine (A) sub-
stitutions at positions 784, 808, 826, 841, and 850 within
the -P-X-X-P- motifs identified in ROR1-PRD (Fig. 6c).
We generated MEC1 cells that each expressed one of
these constructs and found they expressed levels of
ROR1 and cortactin that were similar to that of MEC1-
ROR1, which expressed WT ROR1 (Fig. 6e). ROR1 with
P= > A substitutions at 784, 808, 826, or 850 could
interact and induce phosphorylation of cortactin in
MEC1 cells similar to what we noted for W/T ROR1
(Fig. 6e). Moreover, MEC1 cells expressing any one of
these mutant forms of ROR1 had enhanced F-actin
polymerization in response to CCL21 (Fig. 6f), as did
MEC1 cells expressing W/T ROR1. However, ROR1
with a P= > A substitution at 841 in the PRD domain of
ROR1 (ROR1P(841)A) appeared unable to interact with
cortactin, or enhance cortactin phosphorylation (Fig. 6e).
Moreover, MEC1 cells expressing ROR1P(841)A did not
have enhanced chemokine-directed F-actin polymeriza-
tion, but rather appeared similar to MEC1 cells lacking
ROR1 (Fig. 6f).
Cirmtuzumab, but not ibrutinib, could inhibit
Wnt5a-induced activation of cortactin
Prior studies found that surface immunoglobulin ligation to
induce B-cell-receptor (BCR) signaling could induce
phosphorylation of cortactin [21]. We corroborated these
findings, observing that BCR signaling induced by anti-IgM
(anti-µ) could induce tyrosine phosphorylation of cortactin
at Y421 in CLL cells (Fig. 7a). Treatment of CLL cells with
ibrutinib, a drug that inhibits BTK and BCR signaling [27],
inhibited the capacity of anti-µ to induce cortactin phos-
phorylation (Fig. 7a); but was unable to inhibit the capacity
of Wnt5a to induce phosphorylation of cortactin (Y421)
(Fig. 7b, c). On the other hand, cirmtuzumab could block
Wnt5a-induced cortactin phosphorylation (Fig. 7b, c).
Discussion
In the present study we found that Wnt5a induces ROR1
to associate with cortactin, which undergoes tyrosine
phosphorylation; this effect could be inhibited by the anti-
ROR1 mAb cirmtuzumab. We also found that ROR1/cor-
tactin associated with ARHGEF1, which could activate
RhoA. Specific siRNA-mediated silencing of cortactin, or
treatment with cirmtuzumab, could inhibit the capacity of
Wnt5a to enhance CXCL12-directed CLL-cell migration.
Fig. 5 Cortactin associates with ARHGEF1, which undergoes
cortactin-dependent activation to enhance activation of RhoA.
a Immunoblot analysis of anti-cortactin ip or Ctrl-IgG ip, as indicated
at the top, using lysates prepared from freshly isolated primary CLL
cells; the filters were probed with anti-cortactin or anti-ARHGEF1
antibody, as indicated on the left. b Immunoblot analysis of anti-
ARHGEF1 ip or Ctrl-IgG ip, as indicated at the top, using lysates
prepared from freshly isolated primary CLL cells; filters were probed
with anti-cortactin or anti-ARHGEF1 antibody, as indicated on the
left. c In vitro exchange assay on RhoA of anti-ARHGEF1 ip from
lysates of CLL cells transfected with Ctrl-siRNA (green line) or
siRNA specific for cortactin (red line) in the presence of Wnt5a. The
blue line depicts GTPase-activation using buffer alone. d Immunoblot
analysis of lysates prepared from MEC1-ROR1 cells transfected 72 h
prior with control siRNA or siRNA targeting cortactin; expression of
total RhoA, and activated RhoA was measured, as indicated on the left
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Moreover, siRNA-mediated silencing of coractin or treat-
ment with cirmtuzumab, also inhibited the capacity of CLL-
cells co-cultured with MSC to have enhanced migration.
Collectively, these studies reveal that cortactin plays an
important role on ROR1-dependent non-canonical Wnt5a-
signaling involved in chemokine-directed migration.
The PRD of ROR1 was necessary for it to interact with
cortactin and induce F-actin polymerization in response to
Wnt5a. The SH3 domain of cortactin allows it to bind the
PRD of other proteins at proline residues within -P-X-X-P-
motifs [16–18]. ROR1 with alanine substitutions for proline
at position 841 (ROR1P841A) did not associate with cortactin
in MEC1 cells. Moreover, MEC1 cells transfected with
ROR1P841A had levels of phosphorylated cortactin or
chemokine-directed F-actin polymerization that were com-
parable to that of MEC1 cells lacking ROR1, but sig-
nificantly less than MEC1 cells transfected to express WT
ROR1 or mutant ROR1 with proline to alanine substitutions
at other -P-X-X-P- motifs within the ROR1-PRD. Thus, the
proline residue at 841 of ROR1 appears critical for binding
to cortactin, or possibly another cytosolic protein(s), which
in turn could interact with cortactin. Therefore, this residue
Fig. 6 ROR1P(841)A has impaired capacity to associate with cortactin,
induce cortactin phosphorylation, or enhance chemokine-directed
MEC1-cell F-actin polymerization. a Schematic depicts the structure
of ROR1 protein with different domains. b ΔPRD represents the
truncated form of ROR1 without its PRD. c Amino-acid sequences of
the PRD of ROR1. Asterisks indicate the proline (P) amino-acid
residues that had been substituted with alanine (A). d Interaction of
ROR1 with cortactin was determined by immunoblot analysis of anti-
ROR1 ip from lysates of MEC1 (Ctrl), MEC1-ΔPRD, or MEC1-
ROR1 (W/T) cells as indicated on the top. e Interaction of ROR1 with
cortactin was confirmed by immunoblot analysis of anti-ROR1 ip from
lysates of MEC1, MEC1-ΔPRD, MEC1-ROR1 (W/T), or MEC1 cells
transfected with each of the various mutated forms of ROR1, as
indicated on the top (upper panel). In the lower panel is an immunoblot
of the whole-cell lysates of the MEC1 (Ctrl), MEC1-ΔPRD, MEC1-
ROR1 (W/T), or MEC1 cells transfected with each of the various
mutated forms of ROR1, as indicated on the top, and probed with anti-
cortactin or anti-pCortactin (Y421) antibody. Expression and tyrosine
phosphorylation of cortactin (Y421) was determined in the whole-cell
lysates. f MEC1 (Ctrl), MEC1-ROR1 (W/T), or MEC1 cells trans-
fected with each of the various mutated forms of ROR1, as indicated at
the bottom, were examined for F-actin polymerization in the absence
(–) or presence (+) of chemokine CCL21 (100 ng/ml). Data are shown
as mean ± S.D. from three independent experiments, (n= 3). P < 0.05;
P < 0.01, as calculated using one-way ANOVA with post-hoc Tukey
HSD test
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plays an important role for ROR1 to bind and activate
cortactin and enhance chemokine-directed F-actin poly-
merization of MEC1 cells.
Enhanced CLL-cell motility was associated with phos-
phorylation of cortactin in circulating CLL cells [21]. Other
than Wnt5a, cortactin can undergo phosphorylation in
response to factors such as the chemokine CXCL12, which
can induce chemokine-receptor signaling via CXCR4, or by
anti-µ, which could induce BCR signaling [21]. However,
the results of our study suggest that Wnt5a also may induce
cortactin phosphorylation in CLL cells via ROR1-
dependent signaling [12]. Culturing CLL cells in media
lacking Wnt5a resulted in rapid reduction in the levels of
phosphorylated cortactin, which could be restored by
treatment of CLL cells with exogenous Wnt5a. Similarly,
we found that MEC1 cells have undetectable levels of
phosphorylated cortactin unless they are transfected to
express ROR1, which allows for ROR1 signaling in
response to autocrine Wnt5a. Ibrutinib, at drug concentra-
tions that could block BTK and BCR signaling [27, 28],
could not inhibit the capacity of Wnt5a to induce cortactin
phosphorylation (Y421) or enhance CLL-cell motility.
In a prior study, we found that Wnt5a could induce
activation of RhoA via the recruitment and activation of
ARHGEF1 to ROR1 [12]. We also found that HS1 could
function as an adaptor protein for the recruitment of
ARHGEF1 to ROR1 and could contribute to Wnt5a-
enhanced migration of CLL cells [23]. In the present study
we found that cortactin also can interact with ROR1 and
activate ARHGEF1 to enhance activation of RhoA and
chemokine-directed cell migration [29]. Consistent with the
notion that cortactin plays an important role in such sig-
naling is our finding that leukemia cells with reduced
expression of cortactin following treatment with specific
siRNA were significantly less responsive to Wnt5a, indi-
cating that cortactin contributes to ROR1-signaling leading
to enhanced leukemia-cell migration. Moreover, silencing
of both cortactin and HS1 in CLL cells had an additive
effect on the inhibition of Wnt5a-enhanced chemokine-
directed migration that was significantly greater than that
achieved by silencing either cortactin or HS1 alone. This
indicates that both cortactin and HS1 are involved in the
capacity of Wnt5a to enhance leukemia-cell motility and
that the deficiency of one cannot be fully compensated by
the other. Collectively, these studies reveal that Wnt5a
induces ROR1 to complex with cortactin/HS1/ARHGEF1
at P841, which induces phosphorylation of cortactin and
HS1, activation of ARHGEF1 and RhoA, thereby enhan-
cing leukemia-cell migration.
Fig. 7 Cirmtuzumab, but not ibrutinib, can inhibit wnt5a-induced
activation of cortactin. a Immunoblot analysis of lysates prepared from
overnight, serum-starved primary CLL cells that subsequently were
treated with ibrutinib (0.5 μm), without (–) or with (+) anti-human
IgM F(ab)2 (10 μg/ml), as indicated at the bottom; the filters were
probed with anti-cortactin or anti-pCortactin (Y421) antibody, as
indicated on the left. The numbers above each lane are ratios of band
IOD of phosphorylated versus total cortactin. b Immunoblot analysis
of lysates prepared from overnight, serum-starved primary CLL cells
that subsequently were treated with cirmtuzumab (10 μg/ml) and/or
ibrutinib (0.5 μm), without (–) or with (+) Wnt5a (100 ng/ml), as
indicated at the bottom; the filters were probed with anti-cortactin or
anti-pCortactin (Y421), as indicated on the left. The numbers above
the top lane are ratios of band IOD of phosphorylated cortactin versus
total cortactin. c Phosphorylation of cortactin (Y421) was measured in
serum-starved primary CLL cells that subsequently were treated with
cirmtuzumab (10 μg/ml) and/or ibrutinib (0.5 μm), without (–) or with
(+) Wnt5a (100 ng/ml), as indicated at the bottom. Data are shown as
mean ± SD from three independent experiments, (n= 3). P < 0.001, as
determined by two-tailed Student’s t-test
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Surely, cortactin may facilitate motility of cells that do
not express ROR1, possibly by its capacity to associate with
other cell surface receptors, which induce actin-
cytoskeleton reorganization necessary for cell migration
[13, 18, 30–33]. Indeed, cortactin can facilitate F-actin
polymerization with the association of the Arp2/3 complex
[34, 35]. Mice deficient in cortactin have impaired leuko-
cyte transmigration and defective neutrophil extravasation
[36]. Moreover, cells deficient in cortactin had impaired
motility due to defects in the persistence of lamellipodial
protrusions [37]. In those cases, cortactin contributes to
such cellular functions by interacting with other binding
partners following stimulation of surface receptors other
than ROR1, such as CXCR4 or CCR7 [13, 14, 18, 30–33,
38]. Nevertheless, our studies show that cortactin can
interact with ROR1 and enhance migration of CLL cells
that express ROR1.
In summary, the present study describes a previously
unrecognized activation of RhoA via ROR1/cortactin/
ARHGEF1-dependent mechanism in response to Wnt5a,
which prior studies found is present at high levels in the
plasma of patients with CLL and is presumably present at
even higher levels in lymphoid tissues. Conceivably this
could enhance leukemia-cell migration to and retention
within the lymph nodes, allowing CLL cells' greater
opportunity to receive additional growth/survival factors
from accessory cells within the leukemia microenvironment.
The reported findings highlight a pathway for potential drug
development involving the importance of cortactin in
ROR1-dependent Wnt5a-induced signaling. To this end, we
found that the capacity of Wnt5a to induce ROR1 to interact
and activate cortactin, recruit and activate ARHGEF1, and
enhance leukemia-cell migration could be blocked by cir-
mtuzumab, a first-in-class humanized anti-ROR1 mAb,
which is being evaluated in patients with CLL (https://clinica
ltrials.gov/ct2/show/NCT02222688) [39, 40]. Taken toge-
ther, these studies demonstrate that cirmtuzumab can inhibit
activation of ROR1-dependent growth/survival/migration-
signaling pathways that appear unaffected by treatment with
ibrutinib [28], supporting the rationale for clinical evalua-
tion of this antibody alone or in combination with other
targeted therapies in patients with CLL.
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